The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans. 1982

K J Hoffmann, and A Arfwidsson, and K O Borg

The metabolic routes of the selective beta 1-adrenoceptor agonist prenalterol have been studied in mice, rats, dogs, and humans after oral administration. The drug was well absorbed from the gastrointestinal tract and most of the administered radioactivity was excreted in urine from all species within 24 hr. Prenalterol was metabolized to a varying extent in the species studied. About 20% of the 10-mg dose was recovered unchanged in man, the corresponding figures being 1.8% in the mouse, 7% in the rat, and 54% in the dog at 0.263 mg/kg (1 mumol/kg). Three metabolites were characterized and quantified by thin-layer chromatography, high-performance liquid chromatography, nuclear magnetic resonance (1H and 13C), and gas chromatography-mass spectrometry. Pronounced species variations in the metabolic pattern were observed. The phenolic sulfate ester of prenalterol was the main urinary metabolite in man, important in the dog, minor in the rat but not detectable in the mouse. Prenalterol glucuronide was formed in significant amounts in the animals and, in addition, beta-4(hydroxyphenoxy)lactic acid was present in dog urine. In the rat and the mouse the degree of biotransformation of prenalterol was significantly decreased at high oral doses of 2630 mg/kg (10 mmol/kg). The synthesis of prenalterol sulfate ester with use of ion pair extraction techniques is described.

UI MeSH Term Description Entries
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D008297 Male Males
D008658 Inactivation, Metabolic Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion. Detoxication, Drug, Metabolic,Drug Detoxication, Metabolic,Metabolic Detoxication, Drug,Detoxification, Drug, Metabolic,Metabolic Detoxification, Drug,Metabolic Drug Inactivation,Detoxication, Drug Metabolic,Detoxication, Metabolic Drug,Detoxification, Drug Metabolic,Drug Inactivation, Metabolic,Drug Metabolic Detoxication,Drug Metabolic Detoxification,Inactivation, Metabolic Drug,Metabolic Drug Detoxication,Metabolic Inactivation
D011217 Practolol A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS. Dalzic,Eralzdin Practolol,ICI-50172,ICI 50172,ICI50172,Practolol, Eralzdin
D011294 Prenalterol A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME. A-Ba-C-50,005,H-133-22,H-80-62,KWD-2033,Prenalterol Hydrochloride,A Ba C 50,005,ABaC50,005,H13322,H8062,Hydrochloride, Prenalterol,KWD2033
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic

Related Publications

K J Hoffmann, and A Arfwidsson, and K O Borg
January 1981, European journal of clinical pharmacology,
K J Hoffmann, and A Arfwidsson, and K O Borg
February 1980, European journal of clinical pharmacology,
K J Hoffmann, and A Arfwidsson, and K O Borg
June 1981, The Journal of pharmacy and pharmacology,
K J Hoffmann, and A Arfwidsson, and K O Borg
January 1981, Journal of cardiovascular pharmacology,
K J Hoffmann, and A Arfwidsson, and K O Borg
September 1980, The Journal of pharmacy and pharmacology,
K J Hoffmann, and A Arfwidsson, and K O Borg
January 1984, Journal of cardiovascular pharmacology,
K J Hoffmann, and A Arfwidsson, and K O Borg
May 1993, Biological & pharmaceutical bulletin,
K J Hoffmann, and A Arfwidsson, and K O Borg
January 1983, European journal of clinical pharmacology,
K J Hoffmann, and A Arfwidsson, and K O Borg
January 1985, International journal of clinical pharmacology, therapy, and toxicology,
K J Hoffmann, and A Arfwidsson, and K O Borg
March 1981, Der Anaesthesist,
Copied contents to your clipboard!